13F

TBPH Theravance Biopharma, Inc.

2026Q1 · CUSIP G8807B106 · Sector: Healthcare & Biotech

Neutral · No signal
Holders
170
Δ holders QoQ
+2
Breadth percentile
Top 53%
Whale holders
99
Δ whales
+7
Inst. holding value
$806M
New positions
40
Closed positions
38
Price momentum (1Q)
Put / Call
4/3

Breadth history (34 quarters)

2018Q1: Δ+6 · h=89 2018Q2: Δ-4 · h=85 2018Q3: Δ+7 · h=92 2018Q4: Δ+1 · h=93 2019Q1: Δ+9 · h=102 2019Q2: Δ-7 · h=95 2019Q3: Δ-5 · h=90 2019Q4: Δ+16 · h=106 2020Q1: Δ-3 · h=103 2020Q2: Δ+20 · h=123 2020Q3: Δ-6 · h=117 2020Q4: Δ-11 · h=106 2021Q1: Δ+0 · h=106 2021Q2: Δ+2 · h=108 2021Q3: Δ+9 · h=117 2021Q4: Δ-2 · h=115 2022Q1: Δ+3 · h=118 2022Q2: Δ-6 · h=112 2022Q3: Δ+10 · h=122 2022Q4: Δ-3 · h=119 2023Q1: Δ-7 · h=112 2023Q2: Δ+8 · h=120 2023Q3: Δ-3 · h=117 2023Q4: Δ+3 · h=120 2024Q1: Δ+4 · h=124 2024Q2: Δ+9 · h=133 2024Q3: Δ-13 · h=120 2024Q4: Δ+9 · h=129 2025Q1: Δ+5 · h=134 2025Q2: Δ+3 · h=137 2025Q3: Δ+26 · h=163 2025Q4: Δ+5 · h=168 2026Q1: Δ+2 · h=170 2018Q1: holders=89 2018Q2: holders=85 2018Q3: holders=92 2018Q4: holders=93 2019Q1: holders=102 2019Q2: holders=95 2019Q3: holders=90 2019Q4: holders=106 2020Q1: holders=103 2020Q2: holders=123 2020Q3: holders=117 2020Q4: holders=106 2021Q1: holders=106 2021Q2: holders=108 2021Q3: holders=117 2021Q4: holders=115 2022Q1: holders=118 2022Q2: holders=112 2022Q3: holders=122 2022Q4: holders=119 2023Q1: holders=112 2023Q2: holders=120 2023Q3: holders=117 2023Q4: holders=120 2024Q1: holders=124 2024Q2: holders=133 2024Q3: holders=120 2024Q4: holders=129 2025Q1: holders=134 2025Q2: holders=137 2025Q3: holders=163 2025Q4: holders=168 2026Q1: holders=170 -26 -13 +0 +13 +26 76128179 18Q119Q120Q121Q122Q123Q124Q125Q126Q1 Δ holders (bar) Holders (line)

Past Lit Events & Aftermath 3 lit events

Period Percentile Next-1Q return Next-2Q return
2025Q3 Top 12%
2022Q3 Top 13%
2020Q2 Top 17%

Options Sentiment

Put holders
4
QoQ: +4
Call holders
3
QoQ: 0

See methodology →

Fundamentals

PE (TTM)
7.7
EPS (TTM)
$2.20
EPS YoY
Revenue (TTM)
$0.1B
Revenue YoY
+68.2%
Quarterly Revenue & EPS (4Y)
2022-06-30: $11M 2022-09-30: $12M 2022-12-31: $15M 2023-03-31: $10M 2023-06-30: $14M 2023-09-30: $16M 2023-12-31: $18M 2024-03-31: $15M 2024-06-30: $14M 2024-09-30: $17M 2024-12-31: $19M 2025-03-31: $15M 2025-06-30: $26M 2025-09-30: $20M 2025-12-31: $46M 2026-03-31: $18M 2022-06-30: EPS -0.11 2022-09-30: EPS 12.14 2022-12-31: EPS -0.15 2023-03-31: EPS -0.35 2023-06-30: EPS -0.28 2023-09-30: EPS -0.17 2023-12-31: EPS -0.17 2024-03-31: EPS -0.24 2024-06-30: EPS -0.34 2024-09-30: EPS -0.26 2024-12-31: EPS -0.31 2025-03-31: EPS -0.27 2025-06-30: EPS 1.08 2025-09-30: EPS 0.07 2025-12-31: EPS 1.15 2026-03-31: EPS -0.10 0M 23M 46M $M -0.38 6.48 13.35 20222023202420252026 Revenue EPS

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
4Y median 10 2023-03-31: PE 0.92023-06-30: PE 0.92025-06-30: PE 54.82025-09-30: PE 30.52025-12-31: PE 9.62026-03-31: PE 7.4 1 29 58 20222023202420252026

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-31 · SEC filings (XBRL)